GET THE APP

Epi-genetics and treatment planning for primary glioblastoma
..

Molecular and Genetic Medicine

ISSN: 1747-0862

Open Access

Epi-genetics and treatment planning for primary glioblastoma


International Conference and Exhibition on Molecular Medicine and Diagnostics

August 24-26, 2015 London, UK

Rasime Kalkan

Posters-Accepted Abstracts: J Mol Genet Med

Abstract :

Background: To establish the frequency of MGMT and RARβ methylation in primary glioblastomas. We screened primary
glioblastoma multiforme (GBM) in a population-based study for MGMT and RARβ methylation and correlated them with clinical
data and treatment.
Results: MGMT methylation was detected in 13 of the 40 patients (32.5%). MGMT-promoter methylation did not correlate with
overall survival (OS; p>0.05). RARB methylation was detected in 24 of the 40 patients (60%). The overall survival time of the patients
with methylated RARβ was 19 months, and non-methylated RARB was 15 months. There was statically (OS; p<0.05) significance
between the patients who were treated with chemotherapy and radiotherapy.
Conclusion: In summary, this study is suggested to the RARβ gene is also a new prognostic and predictive candidate marker for the
primary GBM patients for choosing therapy strategy. Furthermore MGMT promoter methylation had no prognostic value and lower
frequency in primary glioblastomas.

Google Scholar citation report
Citations: 3919

Molecular and Genetic Medicine received 3919 citations as per Google Scholar report

Molecular and Genetic Medicine peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward